OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
Margherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
European Journal of Cancer (2024) Vol. 208, pp. 114199-114199
Closed Access | Times Cited: 12
Margherita Rimini, Lorenzo Fornaro, Mario Domenico Rizzato, et al.
European Journal of Cancer (2024) Vol. 208, pp. 114199-114199
Closed Access | Times Cited: 12
Showing 12 citing articles:
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 2
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 2
Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
Annamaria Massa, Francesca Vita, Caterina Peraldo‐Neia, et al.
Cancers (2025) Vol. 17, Iss. 1, pp. 132-132
Open Access | Times Cited: 1
Annamaria Massa, Francesca Vita, Caterina Peraldo‐Neia, et al.
Cancers (2025) Vol. 17, Iss. 1, pp. 132-132
Open Access | Times Cited: 1
EBV enhances immunotherapy sensitivity in intrahepatic cholangiocarcinoma through cGAS-STING pathway activation
Lingli Huang, Qian Zhong, Silan Huang, et al.
Hepatology Communications (2025) Vol. 9, Iss. 4
Open Access
Lingli Huang, Qian Zhong, Silan Huang, et al.
Hepatology Communications (2025) Vol. 9, Iss. 4
Open Access
Efficacy and safety of immune checkpoint inhibitors in advanced biliary tract cancer: a real-world study
Yichen Zheng, Jiamin Guo, Tianhui Ren, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Yichen Zheng, Jiamin Guo, Tianhui Ren, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment
Fuling Huang, Ye‐Ying Fang, Jiaying Wen, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Fuling Huang, Ye‐Ying Fang, Jiaying Wen, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
The Immune–Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies
Antonella Cammarota, Rita Balsano, Tiziana Pressiani, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 272-272
Open Access
Antonella Cammarota, Rita Balsano, Tiziana Pressiani, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 272-272
Open Access
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions
Silvia Camera, Federico Rossari, Silvia Foti, et al.
Targeted Oncology (2025)
Closed Access
Silvia Camera, Federico Rossari, Silvia Foti, et al.
Targeted Oncology (2025)
Closed Access
Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative option for advanced unresectable intrahepatic cholangiocarcinoma: a retrospective real-world study
Zhitao Dong, Chengjun Sui, Jiongjiong Lu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Zhitao Dong, Chengjun Sui, Jiongjiong Lu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data
Patrick Reimann, Ilektra-Antonia Mavroeidi, Jonathan Burghofer, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 12
Open Access
Patrick Reimann, Ilektra-Antonia Mavroeidi, Jonathan Burghofer, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 12
Open Access
Superior survival benefits of triple combination immunotherapy compared to standard chemotherapy as second-line treatment for advanced biliary tract cancer: a retrospective analysis
Peipei Shang, Heming Xu, Tianmei Zeng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Peipei Shang, Heming Xu, Tianmei Zeng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Durvalumab and pembrolizumab in advanced biliary tract cancer: a reconstructed patient-level mimic head-to-head comparative analysis
Bi‐Cheng Wang, Bo‐Hua Kuang, Guo‐He Lin, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Bi‐Cheng Wang, Bo‐Hua Kuang, Guo‐He Lin, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
